News

US FDA to shorten review time for drug developers under new voucher program
The U.S. FDA is launching a program under which its commissioner can issue vouchers to companies he finds are aligned with ...
BIO chair: U.S. has a ‘crisis’ on drug costs
The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.
US FDA to Issue New Vouchers to Drug Developers to Shorten Review Time
(Reuters) -The U.S. Food and Drug Administration on Tuesday announced that it will issue a new priority review voucher to ...
FDA to offer faster drug reviews to companies promoting ‘national priorities’
The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...
FDA Announces New Vouchers to Cut Drug Reviews to Two Months
The US Food and Drug Administration announced a new national priority voucher plan that aims to cut drug review times to one ...
STAT2h
FDA announces a new priority review program in bid to further administration goals
The FDA is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions ...
We Spent a Year Investigating How the FDA Let Risky Drugs Into the U.S. Market
Our investigation exposed a little-known practice inside the FDA that allowed more than 150 drugs or their ingredients into ...
The American Journal of Managed Care3h
FDA Approves Garadacimab-gxii in Hereditary Angioedema
Garadacimab-gxii is the first and only treatment that targets factor XIIa (FXIIa) for the prophylactic prevention of reditary ...
Lab-Grown Salmon Gets FDA Approval
"Transparency is important to us at Wildtype." Wildtype is the third lab-grown meat producer to receive full government ...
US FDA puts on hold Rein Therapeutics' lung disease drug trial
Rein Therapeutics has paused patient enrollment and dosing in a mid-stage trial of its lung disease drug in the U.S. after ...
US FDA extends review of KalVista's swelling disorder drug due to heavy workload
KalVista Pharmaceuticals' said on Friday that the U.S. Food and Drug Administration had extended the review of its drug for a ...